Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

BACKGROUND: Metastatic colorectal cancer (mCRC) that harbours a BRAF V600E mutation (BRAF MT) is associated with poorer outcomes. However, whether this mutation is predictive of treatment benefit from anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) is uncertain. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Rowland, A, Dias, M M, Wiese, M D, Kichenadasse, G, McKinnon, R A, Karapetis, C S, Sorich, M J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580381/
https://www.ncbi.nlm.nih.gov/pubmed/25989278
http://dx.doi.org/10.1038/bjc.2015.173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580381/
https://www.ncbi.nlm.nih.gov/pubmed/25989278
http://dx.doi.org/10.1038/bjc.2015.173

Ejemplares similares